Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
AEON Biopharma
AEON Biopharma named Chris Carr chief financial officer. Carr was previously CFO and executive vice president of finance and IT at Dendreon Pharmaceuticals.
Aerie Pharmaceuticals
Charlene Davis has been named vice president and chief compliance officer at Aerie Pharamceuticals. Davis was previously head of healthcare compliance for North America at Sun Pharmaceutical Industries.
Aeterna Zentaris
Toronto-based Aeterna Zentaris has appointed Klaus Paulini president and chief executive officer and director. Paulini, based in Germany, was most recently managing director and vice president of quality and regulatory with Aeterna Zenartis.
Aidal Pharamaceuticals
Mark Peikin was named chief strategy officer of corporate communications at Aidal Pharmaceuticals. Previously, Peikin was chief executive officer of Bespoke Growth Partners.
Ascletis Pharma
Ascletis Pharma has named Handan He chief scientific officer. He was most recently global head of computational biopharmaceutics and translational PK/PD at Novartis.
Biodesix
Biodesix has appointed James Jett chief medical officer. Jett was most recently CMO with Oncimmune.
BioMarin Pharmaceutical
BioMarin has named Lon Cardon chief scientific strategy officer. Before joining BioMarin, Cardon served as senior vice president of alternative discovery and development and head of target sciences at GlaxoSmithKline.
Catalent
Guy Dewil has been appointed general manager of Catalent’s clinical supply facility in Germany. Dewil is the former vice president of global operations at Syneos Health.
Cerecin
Cerecin has appointed Lilian Chow vice president of clinical operations and regulatory affairs. Chow was most recently with ASLAN Pharmaceuticals where she was vice president of clinical operations, and research and development.
Cue Biopharma
Cue Biopharma has named Anish Suri as president. Suri was most recently chief science officer at Cue Biopharma and will remain in that role.
Cyclica
Vern De Biasi has been named vice president and global head of strategic partnerships with Cyclica. De Biasi most recently served as head of digital data and analytics for GlaxoSmithKline.
GenSight Biologics
Magali Taiel has been named chief medical officer at GenSight Biologics. Taiel was previously vice president of clinical development for GenSight Biologics.
Gilead Sciences
Gilead Sciences has added to its leadership with Merdad Parsey named chief medical officer. Parsey previously served as senior vice president of early clinical development in the Genentech Research and Early Development Group.
Grail
Matthew Young was named chief operating officer and chief financial officer at Grail. Previously, Young was executive vice president and CFO at Jazz Pharamceuticals.
Hepion Pharmaceuticals
Daren Ure has been appointed chief science officer, Daniel Trepanier has been named senior vice president of drug development and Patrick Mayo has been named senior vice president of clinical pharmacology at Hepion Pharmaceuticals. Ure was director of research and development, Trepanier was director of drug development and Mayo was director of clinical pharmacology at Ciclofilin Pharmaceuticals.
Johnson and Johnson
James Swanson has been appointed chief information officer at Johnson and Johnson. Swanson was previously CIO and head of digital transformation for crop science at Bayer and CIO at Monsanto.
MedeAnalytics
Scott Hampel was named president of MedeAnalytics. Previously, Hampel was chief product and strategy officer at the company.
OM1
OM1 has named Gary Curhan chief medical officer. Curhan is a practicing nephrologist in Boston, professor of medicine at Harvard Medical School, professor of epidemiology at Harvard’s School of Public Health and previously served as editor-in-chief for the Clinical Journal of The American Society of Nephrology.
Optinose
Optinose has named Michael Richardson the first vice president of business development. Richardson joined from Princeton BioPharma where he served as vice president of commercial operations.
Parexel
John Bell has been named executive vice president and chief quality officer at Parexel. Previously, Bell served as chief quality officer and senior vice president of corporate quality with Parexel.
Verrica Pharmaceuticals
Verrica Pharmaceuticals has named A. Brian Davis as chief financial officer. Davis most recently served as CFO at Strongbridge Biopharma.
Upcoming Events
-
07May
-
14May